Amarin Corp Plcuk (AMRN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Amarin Corp Plcuk  (NASDAQ: AMRN)


Amarin Plcuk's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Amarin Plcuk's ROI in the second quarter of 2026?
Amarin Corp Plcuk recorded a cumulative net loss of $-27 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -4.75%.

Within the Healthcare sector 216 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1870 to 2920.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -0.8 % 8.53 % 10.73 % 2.73 % -1.88 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 460 598 605 623 625
Return On Investment (TTM) -4.75 % -5.49 % -6.3 % -14.56 % -17.98 %
AMRN's Overall Ranking # 2920 # 1870 # 2554 # 1150 # 2703
Seq. Investment Change TTM -6.74 % -0.5 % 4.02 % 2.78 % 2.03 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -27 -34 -39 -86 -104

AMRN Company Profile >> Back to AMRN Roi Comparisons >> See Annual AMRN Return On Investment



Return On Investment AMRN's Ranking
Within: No.
Industry # 74
Sector # 217
Overall # 2920

Return On Investment Statistics
High Average Low
42.94 %
-37.36 %
-118.93 %
(Jun 30 2012)   (Mar 31 2016)



  News about Amarin Corp Plcuk Return on Investment ROI

The Urgent Need for Regulatory Action to Safeguard Patients from the Ineffective Cardiovascular Drug, Fenofibrate

April 24, 2024



In recent months, Amarin Corporation has been at the forefront of advocating for patient safety and pushing for regulatory action against the prescribing of fenofibrate in patients at risk of cardiovascular events. Supported by the HealthyWomen s Citizen Petition, Amarin brings attention to the risks associated with this drug, which has been proven to provide no benefit in improving cardiovascular outcomes. This article explores Amarin s concerns, sheds light on the valuable contributions made by HealthyWomen s Citizen Petition, and emphasizes the pressing need for the FDA to take immediate action to safeguard patients from the potential harm of fenofibrate.
The Ineffectiveness of Fenofibrate:
Fenofibrate, a medication primarily used for managing high cholesterol and triglyceride levels, has come under scrutiny due to its lack of considerable benefit in improving cardiovascular outcomes. Numerous clinical trials have shown little to no effect on preventing heart attacks, strokes, or other cardiovascular events in patients taking fenofibrate. In light of this evidence, the drug s continued prescription for patients at risk of cardiovascular events raises serious concerns regarding patient safety and public health.





Financial Statements
Amarin Plcuk's II. Quarter Investments $ 460 Millions AMRN's Balance sheet
Amarin Plcuk's II. Quarter Income $ -8 Millions Quarterly AMRN's Income Statement
AMRN's Income by Division See AMRN's Income by Division


AMRN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 489 510 591 632 704
Y / Y Investment Growth -4.16 % -13.68 % -6.54 % -10.2 % 6.16 %
Net Income in Millions -39 -82 -59 -106 8
Y / Y Net Income Growth - - - - -
Annual Return On Investment -7.94 % -16.12 % -10.01 % -16.75 % 1.1 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AMRN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AMRN's Competitors
Subscribers only: Roi for Amarin Plcuk's Suppliers
Subscribers only: Return On Investment for AMRN's Customers

Other Ratios
AMRN's Roa AMRN's Inventory Turnover Ratio AMRN's Growth Rates AMRN's Dividend Statistics
AMRN's Profitability Ratios AMRN's Asset Turnover Ratio AMRN's Dividend Growth
AMRN's Roe AMRN's Valuation Ratios AMRN's Financial Strength Ratios AMRN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:09:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.